8-K: RespireRx Pharmaceuticals Enters Agreements for NIH Grant Support and Faces Potential Trading Downgrade

RespireRx Pharmaceuticals has engaged Alien Technology Transfer for assistance in securing NIH grants for its GABAkines program, while also facing a potential downgrade in its trading market due to disclosure issues.

Summary

• RespireRx Pharmaceuticals has entered into two service agreements with Alien Technology Transfer entities to support its EndeavourRxs GABAkines program.
• The first agreement with ATT India focuses on identifying and applying for NIH funding, with success-based fees ranging from 7% to 10% of the award amount, plus support fees of $8,000 for Phase I and $15,000 for Phase II.
• The second agreement with ATT US provides TABA services, including regulatory affairs consulting and IP management, with fees of $6,500 for Phase I and $50,000 for Phase II, plus monthly accounting service fees ranging from $1,760 to $3,200.
• RespireRx is also facing a 15-day grace period from the OTC Markets Group due to concerns about the currency of its public disclosures, potentially leading to a downgrade to the Expert Market.
• The company is attempting to raise funds to address the disclosure deficiency, but there is no guarantee of success.

Sentiment

Score: 3

Explanation: The document contains both positive and negative elements. The agreements with Alien Technology Transfer are a positive step towards securing funding, but the potential trading downgrade and the need for a capital raise are significant concerns. The overall sentiment is negative due to the uncertainty surrounding the company's ability to resolve its disclosure issues and maintain its listing.

Positives

• The agreements with Alien Technology Transfer could provide valuable support in securing NIH funding for the GABAkines program.
• The success-based fee structure for ATT India aligns their interests with RespireRx's success in obtaining grants.
• The TABA services from ATT US could provide expertise in regulatory affairs and intellectual property management.

Negatives

• The potential downgrade to the Expert Market could significantly limit trading activity and investor access to RespireRx shares.
• The company's inability to confirm current and publicly available disclosures is a serious concern.
• There is no assurance that the company will be able to raise the necessary funds to cure the disclosure deficiency.

Risks

• The company may not be able to secure the necessary funding from the NIH despite the agreements with Alien Technology Transfer.
• The company's shares could become less liquid and more difficult to trade if they are downgraded to the Expert Market.
• The company's financial position is uncertain, as it is attempting to raise funds to address the disclosure deficiency.
• The success fees payable to ATT India could be substantial if the company is successful in securing large grants.

Future Outlook

The company anticipates that trading will be restricted to the expert market at the expiration of the grace period if they are unable to make the required filings. They are attempting to raise funds to cure the deficiency.

Management Comments

• The company believes that it is unlikely that it will be able to make the required filings within the grace period.
• The company is in the process of attempting to raise funds of which no assurance can be provided.

Industry Context

The agreements with Alien Technology Transfer are in line with the trend of biotech companies seeking external expertise to navigate the complex process of securing government grants. The potential trading downgrade highlights the importance of maintaining compliance with disclosure requirements in the public markets.

Comparison to Industry Standards

• Many small biotech companies rely on SBIR/STTR grants for funding, and engaging consultants like Alien Technology Transfer is a common practice.
• The success-based fee structure is typical in the grant consulting industry, aligning the consultant's incentives with the client's success.
• The TABA services offered by ATT US are also standard for companies seeking to commercialize research funded by government grants.
• The potential downgrade to the Expert Market is a significant negative event, as it indicates a failure to meet basic disclosure requirements, which is not typical for publicly traded companies.

Stakeholder Impact

• Shareholders face the risk of a potential trading downgrade and reduced liquidity.
• Employees may be affected by the company's financial uncertainty.
• Customers and partners may be concerned about the company's ability to execute its business plan.

Next Steps

• RespireRx needs to attempt to raise funds to address the disclosure deficiency.
• The company needs to work with Alien Technology Transfer to prepare and submit grant applications to the NIH.
• RespireRx needs to monitor the status of its OTC Markets listing and take steps to avoid a downgrade to the Expert Market.

Key Dates

Keywords

NIH Grants, GABAkines, SBIR/STTR, Alien Technology Transfer, OTC Markets, Expert Market, Funding, Regulatory Affairs, Intellectual Property, TABA Services